PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Analyze analyst forecasts for the company and compare them with competitors.
9.68M
Worse than SAVA's estimated revenue of 50.00M.
-1.93M
Worse than SAVA's estimated ebitda of 0.
-1.38
Worse than SAVA's estimated eps of -0.43.
-41.62M
Worse than SAVA's estimated net income of -18.24M.
-1.93M
Worse than SAVA's estimated ebit of 0.
358.54M
Worse than SAVA's estimated sg&a expense of -66.56B.
Analyze DCF forecasts for the company and compare them with competitors.
81.00K
Better than SAVA's revenue of 0.00.
-92.14%
Better than SAVA's revenue growth rate of -100.00%.
-51.13M
Better than SAVA's ebitda of -95.69M.
-63123.46%
Worse than SAVA's ebitda margin of 100.00%.
-51.92M
Better than SAVA's ebit of -97.22M.
-64098.77%
Worse than SAVA's ebit margin of 100.00%.
790.00K
Better than SAVA's depreciation of 1.53M.
76.68M
Worse than SAVA's total cash of 121.14M.
94662.96%
Better than SAVA's cash as percentage of revenue of 100.00%.
No Data
No DCF data available for this metric in the selected year.
No Data
No DCF data available for this metric in the selected year.
No Data
No DCF data available for this metric in the selected year.
No Data
No DCF data available for this metric in the selected year.
7.95M
Better than SAVA's accounts payable of 10.57M.
9818.52%
Worse than SAVA's payables as percentage of revenue of 100.00%.
-153.00K
Worse than SAVA's capital expenditure of -414.00K.
-188.89%
Better than SAVA's capex as percentage of revenue of 100.00%.
4.99%
Better than SAVA's weighted average cost of capital (wacc) of 5.34%.
5.02%
Better than SAVA's cost of equity of 5.34%.
4.08%
Better than SAVA's cost of debt of 4.40%.
-0.23
Worse than SAVA's beta of -0.58.
30.07M
Better than SAVA's diluted shares outstanding of 41.93M.
1.57M
Worse than SAVA's total debt of 0.00.
49.31M
Worse than SAVA's total equity of 101.06M.
50.89M
Worse than SAVA's total capital of 101.06M.
3.09%
Worse than SAVA's debt weighting of 0.00%.
96.91%
Worse than SAVA's equity weighting of 100.00%.
-51.92M
Better than SAVA's ebiat of -97.22M.
-53.46M
Better than SAVA's unlevered free cash flow of -90.51M.
2.00%
Equal to SAVA's long-term growth rate of 2.00%.
No Data
No DCF data available for this metric in the selected year.
No Data
No DCF data available for this metric in the selected year.
-71.33M
Worse than SAVA's net debt of -121.14M.
71.33M
Worse than SAVA's equity value of 112.01M.
2.37
Worse than SAVA's equity value per share of 2.67.
View analysts' price targets and recommendations, and compare them with competitors.
$11.07
Analysts expect the stock price to increase by 521.91%.
Buy
Positive consensus among analysts.